plerixafor has been researched along with temozolomide in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Boucard, C; Chinot, O; Delfino, C; Denicolai, E; Figarella-Branger, D; Graillon, T; Metellus, P; Nanni, I; Ouafik, L; Padovani, L; Tabouret, E; Tchoghandjian, A | 1 |
1 review(s) available for plerixafor and temozolomide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for plerixafor and temozolomide
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine CXCL12; Chemoradiotherapy; Child; Child, Preschool; Cyclams; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Gene Expression Profiling; Glioblastoma; Heterocyclic Compounds; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Retrospective Studies; Signal Transduction; Temozolomide; Time Factors; Tissue Culture Techniques; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2015 |